Exploring Extended Adjuvant Endocrine Therapy for HR+ Breast Cancer
July 19th 2017Hope S. Rugo, MD, professor of medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses extended adjuvant endocrine therapy for patients with HR+ breast cancer.
Watch
Utilizing Genomic Assays for Decision Making in Early Stage Breast Cancer
July 19th 2017Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses the utility of molecular signatures in managing early-stage breast cancer.
Watch
iFCG Regimen Induces High Rate of Bone Marrow MRD Negativity in IGHV-Mutated CLL
June 22nd 2017The combination regimen of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab achieved a high rate of minimal residual disease-negative status in bone marrow as a first-line treatment in patients with <em>IGHV</em>-mutated chronic lymphocytic leukemia
Read More
Obinutuzumab/Bendamustine Combo Shows Promising Response Rates in Upfront CLL
June 21st 2017The combination of the anti-CD20 monoclonal antibody obinutuzumab and bendamustine induced high rates of complete response and minimal residual disease negativity with no unexpected safety signals as a first-line therapy for patients with chronic lymphocytic leukemia.
Read More
The Potential of Ibrutinib Combinations for the Treatment of CLL
June 16th 2017Javier Pinilla-Ibarz, MD, PhD, associate member, Malignant Hematology and Immunology Program at the H. Lee Moffitt Cancer Center, discusses ongoing research with ibrutinib (Imbruvica) in chronic lymphocytic leukemia.
Watch
Concurrent Treatment With CAR T-Cells, Ibrutinib Leads to Marrow Clearance in Resistant CLL
June 13th 2017Complete marrow clearance of leukemic cells was achieved in 8 of 9 evaluable patients with heavily pretreated or genetically high-risk chronic lymphocytic leukemia who received concurrent treatment with CTL-119 cell therapy and ibrutinib, results of a pilot study showed.
Read More
Ublituximab Added to Ibrutinib Boosts ORR in Patients With Pretreated High-Risk CLL
June 7th 2017Ublituximab (TG-1101) in combination with ibrutinib (Imbruvica) met its primary endpoint of showing an improvement in objective response rate (ORR) compared with ibruitinib monotherapy in patients with previously treated high-risk chronic lymphocytic leukemia (CLL). In a presentation of findings from the phase III GENUINE trial during the 2017 ASCO Annual Meeting, data were reviewed demonstrating that the combination had an ORR of 78% in this patient population.
Read More
Lenalidomide Consolidation Therapy in CLL Demonstrates Notable Survival Plateau
June 7th 2017Lenalidomide consolidation therapy following induction with fludarabine and rituximab (Rituxan) was found to increase long-term survival over survival rates seen with FR or FR plus cyclophosphamide in an overall survival plateau that intrigued researchers when examined in patients with symptomatic, treatment-naive chronic lymphocytic leukemia without an 11q deletion.
Read More
Phase I Results for Enasidenib in AML
June 7th 2017Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I dose escalation and expansion study of enasidenib in mutant <em>IDH-2</em> relapsed or refractory acute myeloid leukemia (AML) during the 2017 ASCO Annual Meeting.
Watch
Significance of the MONARCH 2 Findings for Abemaciclib in HR+/HER2- Breast Cancer
June 7th 2017Peter Kaufman, MD, associate professor of Medicine, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, discusses the significance of the MONARCH 2 trial, which explored abemaciclib in combination with fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer who progressed on endocrine therapy during the 2017 ASCO Annual Meeting.<br />
Watch
Updated Results of the MONALEESA-2 Trial in HR+/HER2- Breast Cancer
June 6th 2017Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses updated results of the phase III MONALEESA-2 trial of first-line ribociclib plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer during the 2017 ASCO Annual Meeting.
Watch
Tripathy Discusses a Study of Talazoparib in BRCA-Mutated Advanced Breast Cancer
June 6th 2017Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the phase II ABRAZO study of talazoparib following platinum or multiple cytotoxic regimens in advanced breast cancer patients with germline <em>BRCA</em> 1/2 mutations during the 2017 ASCO Annual Meeting.
Watch
Exploring Abemaciclib for the Treatment of Brain Metastases in HR+/HER2- Breast Cancer
June 6th 2017Sara M. Tolaney, MD, MPH, associate director, clinical research, breast oncology, Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute, discusses interim results of a trial exploring abemaciclib for the treatment of brain metastases secondary to hormone receptor-positive HER2-negative breast cancer.
Watch
Results of the APHINITY Trial in HER2-Positive Breast Cancer
June 6th 2017Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the APHINITY trial, which compared chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with HER2-positive early breast cancer.
Watch
Early Results Show High Response Rate Achieved With BCMA CAR T-cell Therapy in Multiple Myeloma
June 6th 2017Treatment with chimeric antigen receptor (CAR) T cells that target B-cell maturation protein (BMCA) achieved clinical remissions in 33 out of 35 patients (94%) with relapsed or refractory multiple myeloma in early results from a Chinese study presented at the 2017 ASCO Annual Meeting.
Read More
Epacadostat Added to Pembrolizumab is a Promising Combination in Bladder Cancer
June 6th 2017When epacadostat, an IDO1 inhibitor, was combined with pembrolizumab (Keytruda), a PD-1 inhibitor, responses were seen in 35% of patients with advanced urothelial carcinoma, according to findings presented during the 2017 ASCO Annual Meeting.
Read More
Approximately 25% of patients with <em>BRCA</em> wild-type serous ovarian cancer may benefit from treatment with PARP inhibitors, along with 12.7% of patients with a non-serous histology, according to findings of genomic analyses in patients with ovarian cancer presented during the 2017 ASCO Annual Meeting that demonstrate that comprehensive genomic profiling is a valuable tool to integrate into routine ovarian cancer treatment decision making and clinical trial design.
Read More
Responses Stimulated Across All Tumor Types Harboring TRK Fusions With Larotrectinib
June 6th 2017Larotrectinib (LOXO-101), the novel pan-TRK inhibitor, induced responses in 3 out of 4 patients with a <em>TRK</em> fusion–positive solid tumor, according to findings presented in a press conference June 3 at the 2017 ASCO Annual Meeting.
Read More
Comparing Bosutinib Versus Imatinib in Newly Diagnosed CML
June 6th 2017Jorge Cortes, MD, deputy chair of the Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses initial results from the BFORE trial, which is exploring bosutinib (Bosulif) versus imatinib (Gleevec) for newly diagnosed chronic myeloid leukemia.
Watch
Evaluating Therapy With Encorafenib, Binimetinib, and Ribociclib in Melanoma
June 6th 2017Paola A. Ascierto, MD, medical oncologist, director of Melanoma Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori “Fondazione G. Pascal,” discusses results of a phase Ib/II dose-escalation study evaluating triple combination therapy with encorafenib, binimetiinib, and ribociclib (Kisquali) in patients with <em>BRAF V600</em> solid tumors and melanoma.
Watch
LAG-3 Antibody Combo Active in Patients With Immunotherapy-Treated Melanoma
June 6th 2017More than half of patients with immunotherapy-relapsed/refractory melanoma benefited from treatment with nivolumab and an anti-lymphocyte activation gene-3 (LAG-3) antibody, according to data from an early clinical study.
Read More
Ipatasertib/Paclitaxel as First-Line Therapy Improved PFS in Triple-Negative Breast Cancer
June 6th 2017The experimental AKT inhibitor ipatasertib in combination with paclitaxel improved progression-free survival (PFS) as a first-line therapy for patients with locally advanced or metastatic triple-negative breast cancer when compared with paclitaxel alone, according to initial findings of the LOTUS trial presented during the 2017 ASCO Annual Meeting.<br />
Read More
Alectinib Improved PFS by 15 Months Over Crizotinib in ALK+ NSCLC in ALEX Trial
June 5th 2017Second-generation ALK inhibitor alectinib (Alecensa) demonstrated a 15-month improvement in progression-free survival compared with crizotinib (Xalkori), the first-generation ALK inhibitor and standard of care, in patients with <em>ALK</em>-positive non–small cell lung cancer.
Read More
Intracranial Response 58% With Dabrafenib/Trametinib Combination in BRAF V600 Melanoma
June 5th 2017Dabrafenib (Tafinlar) plus trametinib (Mekinist) achieved an intracranial response (IR) rate of 58% in melanoma that has metastasized to the brain. The median duration of overall response (OR) of 6.5 months was generally shorter than that observed in melanoma patients without brain metastases. These initial findings from the phase II COMBI-MB trial were presented during an oral abstract session at the 2017 ASCO Annual Meeting.
Read More
Lurbinectedin Active in Endometrial Cancer as Monotherapy and in Combination Regimens
June 5th 2017Lurbinectedin (PM01183) shows activity as a single agent as well as in combination with doxorubicin or paclitaxel in patients with advanced endometrial cancer, according to findings presented during the 2017 ASCO Annual Meeting.
Read More
In updated findings from the KEYNOTE-059 trial of pembrolizumab in advanced gastric or gastroesophageal junction (GEJ) cancer, the PD-1 inhibitor maintained signs of its clinical benefit in this patient population, which is encouraging as the indication is currently under consideration for approval with the FDA.
Read More
Select GI AEs Managed in Studies of Nivolumab, Ipilimumab in Melanoma in Pooled Post-Hoc Analysis
June 5th 2017Nivolumab (Opdivo) plus ipilimumab (Yervoy) or ipilimumab alone are associated with a high incidence of gastrointestinal (GI) toxicity, but most adverse events (AEs) are effectively managed using immunomodulators, which do not appear to inhibit tumor response. Additionally, nivolumab plus ipilimumab significantly improved overall survival (OS) and objective response rate (ORR) versus ipilimumab alone in patients with untreated advanced melanoma.
Read More
Immune Component May Affect Survival after Targeted Therapy for Melanoma
June 5th 2017Overall survival in advanced melanoma treated with targeted therapy had a strong association with high PD-L1 expression and high levels of tumor infiltrating lymphocytes, analysis of tissue specimens from a randomized trial showed.
Read More
An Overview of a Study Exploring Mirvetuximab Soravtansine in Ovarian Cancer
June 5th 2017Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses results of an ongoing clinical trial exploring mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant epithelial ovarian cancer patients, during the 2017 ASCO Annual Meeting.
Watch